首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
Institution:1. Synthetic Medicinal Modalities, Integrated Drug Discovery Germany, Sanofi, Frankfurt, Germany;2. TA Diabetes, Sanofi, Frankfurt, Germany;3. Antaros Medical AB, Mölndal, Sweden;4. Science For Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden;5. PET Centre, Centre for Medical Imaging, Uppsala University Hospital, Uppsala, Sweden;6. Preclinical Safety, Sanofi, Frankfurt, Germany;7. Translational Medicine & Early Development, Sanofi, Frankfurt, Germany;8. Clinical Sciences & Operations, Sanofi, Frankfurt, Germany;9. Clinical Sciences & Operations, Sanofi, Chilly-Mazarin, France;10. Diabetes Development, Sanofi, Frankfurt, Germany;11. NOCCR Alliance for Multispecialty Research (AMR), Knoxville, TN, USA
Abstract:
><ol class=
  • Download : Download high-res image (224KB)
  • Download : Download full-size image
  • Keywords:GCG  GIP  GLP-1  metabolic disease  pharmacodynamics  receptor occupancy  safety  triple GLP-1/GIP/GCG receptor agonist  type 2 diabetes
    本文献已被 ScienceDirect 等数据库收录!
    设为首页 | 免责声明 | 关于勤云 | 加入收藏

    Copyright©北京勤云科技发展有限公司  京ICP备09084417号